Alexandria (Alex) Cogdill, MEng, PhD

Alexandria (Alex) Cogdill, MEng, PhD is an accomplished leader in the biopharmaceutical industry, currently serving as the Head of Strategic Initiatives, Global Business Development at Daiichi Sankyo US.1 She has a strong background in oncology and immunotherapy research, as evidenced by her engagement with developments in CAR and TCR-based cell therapies.2

Dr. Cogdill's career trajectory includes:

Education and Achievements

• She holds both a Master of Engineering (MEng) and a PhD, indicating a strong technical and research background.1
• In 2019, she was awarded a Fulbright U.S. Student Research Award, which allowed her to continue her research.6

Professional Experience

Previously, Dr. Cogdill held the position of SVP, Global External Innovation at Daiichi Sankyo, Inc.3 This role likely involved identifying and pursuing innovative opportunities for the company on a global scale.

Research Interests

Dr. Cogdill demonstrates a keen interest in cutting-edge cancer treatments, particularly:

• Next-generation CAR (Chimeric Antigen Receptor) therapies
• TCR (T Cell Receptor) cancer therapies2

She also shows an appreciation for pioneering work in the field, as evidenced by her acknowledgment of distinguished oncologist Steven Rosenberg's contributions to immunotherapy.5

Professional Network

Dr. Cogdill appears to be well-connected in the biotech and pharmaceutical industries, often engaging with colleagues and sharing insights on LinkedIn about innovation, partnerships, and developments in oncology.4

Alexandria Cogdill's expertise in strategic initiatives and global business development, combined with her strong scientific background, positions her as a valuable asset in bridging the gap between scientific innovation and business strategy in the biopharmaceutical sector.